Recent Formulary Updates
Testosterone (transdermal): Specialist initiation (including GPs with a special interest) in hyposexual desire disorder (HSDD) in menopausal women
Daridorexant (Quviviq®): Green for treating long-term insomnia in line with NICE TA922
Tirzepatide (Mounjaro®): Green for type 2 diabetes in line with NICE TA924
GLP-1 agonists: Green for type 2 diabetes in accordance with relevant NICE guidance
Fortisip PlantBased®: Specialist recommendation by a senior dietitian for patients following a vegan diet.
Prosource TF ENFit®: Specialist recommendation for patients receiving home enteral nutrition as a tube feed.
Dapagliflozin (Forxiga®) and Empagliflozin (Jardiance®): Specialist recommendation for treating chronic heart failure with preserved or mildly reduced ejection fraction. Resources: Cheshire and Merseyside APG (Dec 2023) - DAPAGLIFLOZIN and EMPAGLIFLOZIN for symptomatic chronic heart failure with preserved or mildly reduced ejection fraction
Rimegepant (Vydura®): Specialist recommendation for acute migraine. Resources: Cheshire and Merseyside APG (Dec 2023) - RIMEGEPANT oral lyophilisate (Vydura®) for treating acute migraine
Rimegepant (Vydura®): Specialist retains patient for preventing migraine. Resources: Cheshire and Merseyside APG (Sept 2023) - RIMEGEPANT oral lyophilisate (Vydura®) for preventing migraine in adults
Melatonin: preferred formulations updated.
Semaglutide (Wegovy®): Specialist only prescription, for use within a specialist weight management service.
Inclisiran (Leqvio®): updated NHS England documents including supply information
Continuous Glucose Monitoring: updated Primary Care Decision Aids
|